Equities

Guardant Health Inc

Guardant Health Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)25.39
  • Today's Change0.31 / 1.24%
  • Shares traded2.00m
  • 1 Year change-7.97%
  • Beta1.1131
Data delayed at least 15 minutes, as of Sep 19 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy11
Outperform10
Hold1
Sell1
Strong Sell0

Share price forecast in USD

The 19 analysts offering 12 month price targets for Guardant Health Inc have a median target of 40.00, with a high estimate of 60.00 and a low estimate of 23.00. The median estimate represents a 57.54% increase from the last price of 25.39.
High136.3%60.00
Med57.5%40.00
Low-9.4%23.00

Earnings history & estimates in USD

On Aug 07, 2024, Guardant Health Inc reported 2nd quarter 2024 losses of -0.84 per share.
The next earnings announcement is expected on Nov 04, 2024.
Average growth rate-18.56%
Guardant Health Inc reported annual 2023 losses of -4.28 per share on Feb 22, 2024.
Average growth rate-72.60%
More ▼

Revenue history & estimates in USD

Guardant Health, Inc. had 2nd quarter 2024 revenues of 177.24m. This bettered the 162.70m consensus of the 21 analysts covering the company. This was 37.70% above the prior year's 2nd quarter results.
Average growth rate+6.64%
Guardant Health, Inc. had revenues for the full year 2023 of 563.95m. This was 25.45% above the prior year's results.
Average growth rate+27.46%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.